Funding for this research was provided by:
U.S. Department of Defense (W81XWH-11-1-0530, W81XWH-11-1-0531)
Breast Cancer Research Foundation
National Cancer Institute (5P30CA16087)
Received: 1 March 2019
Accepted: 10 June 2019
First Online: 11 July 2019
Ethics approval and consent to participate
: All patients were enrolled in accordance with approved protocols, international standards of good clinical practice, institutional review board approvals, and institutional safety monitoring. Written informed consent was obtained.
: Not applicable.
: The authors declare no competing financial interests related to this manuscript, but SCF has received advisory/ speaker compensation from Sanofi, Regeneron, Elekta, EMD Serono, Merck, Astra Zeneca, Bayer and research support from Varian, Bristol-Myer Squibb, Regeneron, Eisai, Merck and Janssen, and SD has received compensation for consultant/advisory services from Lytix Biopharma, AstraZeneca, Mersana Therapeutics and EMD Serono, and research support form Lytix Biopharma and Nanobiotix.